Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis

Ann Intern Med. 1998 Aug 15;129(4):299-302. doi: 10.7326/0003-4819-129-4-199808150-00006.

Abstract

Background: Despite the widespread use of subcutaneous heparin in the initial treatment of deep venous thrombosis, there are no guidelines for achieving adequate anticoagulation with this drug.

Objective: To implement a weight-based algorithm for the administration of subcutaneous unfractionated heparin after an intravenous loading dose.

Design: Prospective cohort study.

Setting: University hospital.

Participants: 70 outpatients with proximal venous thrombosis.

Intervention: An intravenous bolus of heparin followed by a subcutaneous injection of heparin in doses adjusted for body weight. Subsequent adjustments of the subcutaneous heparin dose were scheduled twice daily according to the algorithm; the activated partial thromboplastin time (aPTT) was measured in the mid-interval (target range, 50 to 90 seconds).

Results: The therapeutic threshold aPTT (> or = 50 seconds) was achieved in 61 patients (87%) within 24 hours and in 69 patients (99%) within 48 hours. In 7 patients (10%), a supratherapeutic aPTT lasted more than 12 hours. No major bleeding episodes or cases of heparin-induced thrombocytopenia were seen. Three patients (4.3% [95% CI, 0.9% to 12.0%]) had recurrent thromboembolism during 3 months of follow-up.

Conclusion: The administration of subcutaneous heparin according to a weight-based algorithm allows the rapid achievement of effective and safe anticoagulation in patients with deep venous thrombosis.

MeSH terms

  • Aged
  • Algorithms
  • Anticoagulants / administration & dosage*
  • Anticoagulants / therapeutic use
  • Body Weight
  • Drug Administration Schedule
  • Female
  • Heparin / administration & dosage*
  • Heparin / therapeutic use
  • Humans
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Partial Thromboplastin Time
  • Prospective Studies
  • Thrombophlebitis / drug therapy*

Substances

  • Anticoagulants
  • Heparin